Clinicopathologic features of KRAS G12C-mutated non-small cell lung carcinomas:insights from 279 retrospective cases
Martina Bradová, Petr Slavík, Tomáš Vaněček, Petr Martínek, Petr Grossmann, Stanislav Kormunda, Kristýna Behenská, Martin Svatoň, Miloš Pešek, Tomáš Jirásek, Zuzana Špůrková, Petra Hroudová, Hana Mrázková, Barbora Hořavová, Jaromír Roubec, Martin Baník, Petr Mukenšnábl, Michal Michal, Marián Švajdle · 2026
Read Clinicopathologic features of KRAS G12C-mutated non-small cell lung carcinomas:insights from 279 retrospective cases by Martina Bradová, Petr Slavík, Tomáš Vaněček, Petr Martínek, Petr Grossmann, Stanislav Kormunda, Kristýna Behenská, Martin Svatoň, Miloš Pešek, Tomáš Jirásek, Zuzana Špůrková, Petra Hroudová, Hana Mrázková, Barbora Hořavová, Jaromír Roubec, Martin Baník, Petr Mukenšnábl, Michal Michal, Marián Švajdle (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13369689.txt.
Description
KRAS G12C-mutated non-small cell lung carcinoma (NSCLC), caused by a glycine-to-cysteine substitution at codon 12, is associated with poor prognosis and is now targetable with specific inhibitors. We retrospectively analyzed 279 KRAS G12C-mutated NSCLC cases (2017–2023) from our registry with available histologic, immunohistochemical, and molecular data.
Catalog record
| CREATOR | Martina Bradová, Petr Slavík, Tomáš Vaněček, Petr Martínek, Petr Grossmann, Stanislav Kormunda, Kristýna Behenská, Martin Svatoň, Miloš Pešek, Tomáš Jirásek, Zuzana Špůrková, Petra Hroudová, Hana Mrázková, Barbora Hořavová, Jaromír Roubec, Martin Baník, Petr Mukenšnábl, Michal Michal, Marián Švajdle |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |